Sustained-Release Neural Ablation Matrix
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases such as hypertension and heart failure through sympathetic nerve modulation are limited by the need for oral medications with poor compliance and energy-based ablation procedures that are anatomically restricted, and acute drug delivery methods that face tissue toxicity issues.
Innovation Solution
A sustained-release formulation incorporating a denervation drug into a polycarbonate or fluoropolymer matrix, which forms microparticles or nanoparticles for gradual release to ablate autonomic neural tissue, targeting renal, carotid, pulmonary, and cardiac sympathetic nerves.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If oral medications are used for sympathetic nerve treatment, then treatment accessibility is improved, but patient compliance deteriorates
Solution Approach 1:
The patent replaces the mechanical/oral medication system with a minimally invasive catheter-based delivery system that directly transports the denervation formulation to the target sympathetic nerve tissue, eliminating the need for oral administration and improving both accessibility and compliance through procedural rather than pharmacological means
2Reliability
If energy-based ablation procedures are used, then treatment efficacy is improved, but anatomical accessibility deteriorates
Solution Approach 1:
The patent introduces a liquid or gel-based denervation formulation as an intermediary medium that can be delivered through a catheter to various sympathetic nerve locations, enabling effective ablation at multiple anatomical sites including renal, carotid, pulmonary, and cardiac sympathetic nerves that are difficult to access with traditional energy-based methods
Solution Approach 2:
The patent changes the delivery parameter from energy-based (heat, radiofrequency, microwave) to chemical-based (denervation formulation), allowing the treatment to be adapted to different anatomical locations by adjusting the formulation composition and delivery parameters rather than being constrained by the limitations of energy transmission
3Speed
If acute drug delivery is used, then treatment speed is improved, but tissue toxicity deteriorates
Solution Approach 1:
The patent employs periodic or controlled release of the denervation formulation through a sustained-release matrix system that gradually releases the active ingredient over time, allowing the treatment to proceed at an appropriate speed while preventing acute toxicity by distributing the drug load over an extended period rather than delivering it all at once
Solution Approach 2:
The patent changes the delivery parameter from acute/high-dose to sustained-release/low-dose, adjusting the release rate and total dose parameters to achieve effective neural ablation while minimizing tissue toxicity through controlled, gradual drug delivery rather than rapid high-concentration exposure
Data Source
AI summary
A denervation formulation including a denervation drug incorporated into a sustained-release matrix. The sustained-release matrix may include a polycarbonate and a fluoropolymer. The sustained-release matrix may form a plurality of particles to encapsulate the denervation drug. The denervation formulation may be delivered to a patients autonomic neural tissue, including but not limited to a renal sympathetic nerve, a carotid nerve, a pulmonary nerve, and/or a cardiac sympathetic nerve. Upon release, the denervation drug may ablate the patients autonomic neural tissue for treatment of cardiac disease, including but not limited to hypertension, heart failure, and/or atrial and ventricular tachycardia.